Celerion published a recorded webinar titled Best Practices in Clinical Gene Therapy Method Development featuring an AAV Vector Shedding Assay.
Published
Signal category
Research & Knowledge
Quote
“Watch our recorded webinar, Best Practices in Clinical Gene Therapy Method Development, featuring an AAV Vector Shedding Assay”
— Celerion team
Company
Celerion
Celerion Can Take You from First-In-Human through Proof-of-Concept.
- Industry
- Pharmaceutical Manufacturing
- Location
- Lincoln, US
- Company size
- 1,190 employees
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com
Founded 2010